PF-06463922 5109 HCl GSK923295 inhibits release of inorganic

GSK923295 inhibits release of inorganic phosphate and stabilized CENP-E motor domain interaction with microtubules

NO synthase activation

Pharmacology of basimglurant (RO4917523

20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11H

Molecular Weight: 1347

PF-06463922 5109 HCl GSK923295 inhibits release of inorganicLorlatinib, also known as PF 06463922, is an orally available, ATP competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, ALK ROS1 inhibitor PF 06463922 binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK and ROS1 mediated signaling and eventually inhibits tumor cell growth in ALK and